SINOVAC Dispatches First Shipment of 23-valent Pneumococcal Vaccine to Azerbaijan

BEIJING, Apr. 21, 2025 — Sinovac Biotech Ltd. ("SINOVAC" or the "Company") has dispatched the inaugural shipment of its 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) to Azerbaijan. The vaccines, produced by the Company's subsidiary, Sinovac Biotech Co., Ltd., will support local public health efforts to prevent and control pneumococcal-related diseases.

Pneumococcal bacteria are the most common cause of community-acquired pneumonia. Estimates from the World Health Organization (WHO) indicate that pneumococcal diseases lead to approximately 1.6 million deaths annually, primarily affecting infants and the elderly. In 2008, the WHO categorized pneumococcal disease as a "very high priority" for vaccine prevention.¹

The PPV23 vaccine is SINOVAC's first bacterial vaccine product to receive marketing authorization. Since its launch in 2020, the vaccine has been utilized across numerous provinces in Mainland China and has been authorized for use in the Chinese Hong Kong and Macau Special Administrative Regions.

At the same time, SINOVAC continues to increase the international availability of the vaccine, having previously supplied the product to Côte d'Ivoire. 

This delivery builds on an established period of cooperation between SINOVAC and Azerbaijan's health authorities. During the COVID-19 pandemic, SINOVAC provided a total of 7.75 million vaccine doses to support the country’s national immunization campaign. 

Reference

1. Meeting of the Immunization Strategic Advisory Group of Experts, November 2007--conclusions and recommendations. Wkly Epidemiol Rec. 2008;83(1):1-15.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.

SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis  vaccine (sIPV), and the live attenuated varicella vaccine.

SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.

With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.

For more information, please see the Company's website at www.sinovac.com.